PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Endocrinology and Metabolism10.3803/enm.2017.32.1.90201732190Development of Clinical Data Mart of HMG-CoA Reductase Inhibitor for Varied Clinical ResearchHun-Sung Kim, Hyunah Kim, Yoo Jin Jeong, Tong Min Kim, So Jung Yang, Sun Jung Baik, Seung-Hwan Lee, Jae Hyoung Cho, In Young Choi, Kun-Ho Yoonhttps://synapse.koreamed.org/pdf/10.3803/EnM.2017.32.1.90, https://synapse.koreamed.org/DOIx.php?id=10.3803/EnM.2017.32.1.90, https://synapse.koreamed.org/DOIx.php?id=10.3803/EnM.2017.32.1.90
Diabetes Research and Clinical Practice10.1016/0168-8227(87)90147-119873S76P-7-29 Long term effect of the HMG CoA reductase inhibitor (CS-514) on lipid and glucose metabolism of hyperlipidemic diabeticshttps://api.elsevier.com/content/article/PII:0168822787901471?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:0168822787901471?httpAccept=text/plain
Clinical Cardiology10.1002/clc.4960171603200917S4IV-3-IV-10The pharmacology of fluvastatin, a new HMG-CoA reductase inhibitorWilliam R. Garnetthttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fclc.4960171603, https://onlinelibrary.wiley.com/doi/full/10.1002/clc.4960171603
Clinical Cardiology10.1002/clc.4960240705200124S210-13Newer HMG-CoA reductase inhibitor (statin) therapiesEliot A. Brintonhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fclc.4960240705, http://onlinelibrary.wiley.com/wol1/doi/10.1002/clc.4960240705/fullpdf
Atherosclerosis10.1016/s0021-9150(98)00014-81998138111-24HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials dataJohn R Crouse III, Robert P Byington, Curt D Furberghttps://api.elsevier.com/content/article/PII:S0021915098000148?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0021915098000148?httpAccept=text/plain
Clinical Therapeutics10.1016/s0149-2918(96)80114-719961820-21C4. Cost-effectiveness trends of HMG-CoA reductase inhibitor therapy in a managed-care populationA. Petitta, R.E. Ward, J.V. Anandan, S.J. Beis, A.M. Johnsonhttps://api.elsevier.com/content/article/PII:S0149291896801147?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0149291896801147?httpAccept=text/plain
Clinical Therapeutics10.1016/s0149-2918(00)88280-61999211218-235Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapyMichael B. Bottorff, Joseph P. Yenkowsky, Douglas G. Cavehttps://api.elsevier.com/content/article/PII:S0149291800882806?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0149291800882806?httpAccept=text/plain
British Journal of Clinical Pharmacology10.1111/j.1365-2125.1990.tb03626.x1990292239-243Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects.SM Singhvi, HY Pan, RA Morrison, DA Willardhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2125.1990.tb03626.x, http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2125.1990.tb03626.x/fullpdf
European Journal of Clinical Pharmacology10.1007/bf014094011991401S15-S18Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductaseH. Y. Panhttp://link.springer.com/content/pdf/10.1007/BF01409401.pdf, http://link.springer.com/article/10.1007/BF01409401/fulltext.html, http://link.springer.com/content/pdf/10.1007/BF01409401
European Journal of Clinical Pharmacology10.1007/bf03216282199140S1S15-S18Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductaseH. Y. Panhttp://link.springer.com/content/pdf/10.1007/BF03216282.pdf, http://link.springer.com/article/10.1007/BF03216282/fulltext.html, http://link.springer.com/content/pdf/10.1007/BF03216282